Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Panobinostat and everolimus may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth and by blocking blood flow to the cancer. Giving
panobinostat together with everolimus may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when
given together with everolimus in treating patients with relapsed or refractory lymphoma or
multiple myeloma.